Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a ...

AstraZeneca executives told Fierce they are “very confident” in the pharma’s in-house pipeline of antibody-drug conjugates ...

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been dosed in the ...

Oral health is known to be linked to overall health, and research has shown relationships with a variety of diseases. Impaired oral health has been linked to prognosis in colorectal cancer and ...

The only TIL therapy approved so far is Amtagvi for melanoma. Here are six companies with promising TIL therapies in the ...

Patients with new-onset diabetes needing rapid treatment escalation or an intense initial regimen had an increased pancreatic ...

Key Points Interested in HUTCHMED (China) Limited Sponsored ADR? Here are five stocks we like better. HUTCHMED remained ...

Carly Simon has been diagnosed with Parkinson's disease while also undergoing treatment for skin cancer. Here's what to know ...

Positive high-level results from the CLARITY-Gastric01 global Phase III trial showed that sonesitatug vedotin (Sone-Ve) demonstrated a statistically significant and highly clinically meaningful ...

AnaptysBio (ANAB) stock shifts to a lean royalty company tied to GSK’s Jemperli. Jemperli royalties escalate with sales. Read ...

US FDA grants priority review status to Johnson & Johnson’s sBLA for Rybrevant Faspro for adults with recurrent or metastatic HNSCC: Raritan, New Jersey Saturday, August 1, 2026 ...

H1’27 catalysts with tagmokitug/casdozokitug readouts and rising Loqtorzi sales—plus CCR8 data upside. Click here to read ...